公开(公告)号：EP1744162A4

公开(公告)日：2007-07-11

申请号：EP05728904

申请日：2005-03-31

申请人： ABURATANI HIROYUKI ,  PERSEUS PROTEOMICS INC ,  CHUGAI PHARMACEUTICAL CO LTD

发明人： ABURATANI HIROYUKI ,  HIPPO YOSHITAKA ,  WATANABE AKIRA ,  FUKAYAMA MASASHI ,  ITO YUKIO ,  ARAI MASAHIRO ,  ITO HIROTAKA ,  OHTOMO TOSHIHIKO ,  FUNAHASHI SHIN-ICHI ,  KINOSHITA YASUKO

IPC分类号： G01N33/574 ,  C07K16/30 ,  C12N15/02 ,  C12N15/09 ,  G01N33/576

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  G01N33/57438 ,  G01N33/57488 ,  G01N33/576

摘要： A method of cancer diagnosis characterized in that ROBO1 protein is detected. Further, there is disclosed a method of treating diseases attributed to abnormal cell growth, comprising administering an antibody capable of binding to ROBO1, and are disclosed, comprising an antibody capable of binding to ROBO1 as an active ingredient, a pharmaceutical composition, cytostatic agent and anticancer agent. Still further, there is disclosed a method of inhibiting the growth of ROBO1 expression cells or method of inducing cytotoxicity in ROBO1 expression cells, comprising bringing an antibody capable of binding to ROBO1 into contact with ROBO1 expression cells. Moreover, there is disclosed a method of monitoring the intensification of hepatitis severity, comprising detection of ROBO1 protein.

摘要翻译： 公开了一种诊断癌症的方法，包括检测ROBO1蛋白。 此外，用于治疗由异常细胞生长引起的疾病的方法包括施用与ROBO1结合的抗体，以及药物组合物，细胞生长抑制剂和抗癌剂，其包含结合ROBO1作为有效成分的抗体的方法， 披露。 此外，公开了通过使ROBO1表达细胞与与ROBO1结合的抗体接触来抑制ROBO1表达细胞中的细胞损伤的方法和抑制ROBO1表达细胞的生长的方法。 此外，公开了通过检测ROB01蛋白来监测肝炎进展的方法。

公开(公告)号：EP1652923A4

公开(公告)日：2006-07-26

申请号：EP04771625

申请日：2004-08-06

申请人： PERSEUS PROTEOMICS INC ,  CHUGAI PHARMACEUTICAL CO LTD ,  ABURATANI HIROYUKI

发明人： ABURATANI HIROYUKI ,  HIPPO YOSHITAKA ,  TANIGUCHI HIROKAZU ,  CHEN YONG XIN ,  ISHIKAWA SHUMPEI ,  FUKUMOTO SHIN-ICHI ,  SHIMAMURA TAKAHIRO ,  KAMIMURA NAOKO ,  GUO YING QIU ,  YAMAMOTO SHOGO ,  ITO YUKIO ,  ITO HIROTAKA ,  OHTOMO TOSHIHIKO

IPC分类号： C12N15/12 ,  A61K31/711 ,  A61K38/00 ,  A61K39/00 ,  C07K14/82 ,  C07K16/30 ,  C07K16/32 ,  C12N5/10 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  A61K31/711 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/82 ,  C07K16/30 ,  C12Q2600/136 ,  G01N33/57484

摘要： A protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOS:1 to 65 or its fragment; an antibody recognizing the same or an antigen-binding fragment thereof; and a polynucleotide having a nucleotide sequence comprising at least 12 consecutive nucleotides in any of the nucleotide sequences represented by SEQ ID NOS:1 to 65 or a nucleotide sequence complementary thereto: The above gene and protein are useful as diagnostics and remedies for cancer.

摘要翻译： 由具有序列号1〜65中任一项所示的碱基序列的基因或其片段编码的蛋白质; 识别相同抗体的抗体或其抗原结合片段; 以及具有在序列号1〜65所示的碱基序列中的任一个碱基序列中具有至少12个连续碱基的碱基序列或与其互补的碱基序列的多核苷酸。上述基因和蛋白质作为癌的诊断和治疗是有用的。

公开(公告)号：EP1589101A4

公开(公告)日：2006-01-18

申请号：EP03768371

申请日：2003-12-26

申请人： CHUGAI PHARMACEUTICAL CO LTD ,  TOUDAI TLO LTD

发明人： ABURATANI HIROYUKI ,  ITO HIROTAKA ,  ISHIKAWA SHUNPEI ,  FUKUMOTO SHINICHI

IPC分类号： C07K14/705 ,  G01N33/574 ,  C12N15/09 ,  G01N33/53

CPC分类号： G01N33/57423 ,  C07K14/705

摘要： It is intended to provide a novel protein showing overexpression specifically in an abnormal cell or an abnormal tissue; a diagnostic method and a diagnostic kit for a disease in which the overexpression of a gene encoding the above protein participates; and a screening method and a screening kit for a preventive/remedy for a disease in which the overexpression of a gene encoding the above protein participates. To achieve these objects, there is provided a novel protein showing overexpression specifically in an abnormal cell or an abnormal tissue which is: (a) a protein comprising the amino acid sequence represented by SEQ ID NO:2, or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:2 by deletion, substitution or addition of one or more amino acids and showing overexpression specifically in an abnormal cell or an abnormal tissue. The expression level of a gene encoding this protein is employed as an indication in diagnosing a disease. Also, an effect of lowering the expression level of the gene encoding this protein is employed as an indication in screening a preventive/remedy for a disease.

公开(公告)号：EP2436397A4

公开(公告)日：2014-02-19

申请号：EP10780608

申请日：2010-05-27

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： YOSHIDA KENJI ,  ITO HIROTAKA

IPC分类号： C07K16/22 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/22 ,  A61K45/06 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/5011 ,  G01N2333/4703 ,  G01N2333/485

摘要： The present inventors identified inhibition of a combination of EGFR ligands that serve as targets for inhibition of cancer cell proliferation. More specifically, EREG antagonists and TGF± antagonists were found to be useful as inhibitors of cell growth. The present invention relates to pharmaceutical compositions containing EGF family ligand antagonists as components.

公开(公告)号：EP1260584A4

公开(公告)日：2004-05-19

申请号：EP01904475

申请日：2001-02-15

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： TSUCHIYA MASAYUKI ,  SAITO MIKIYOSHI ,  ITO HIROTAKA ,  ASHIHARA MOTOOKI ,  OHTOMO TOSHIHIKO

IPC分类号： C07K14/47 ,  C07K14/705 ,  C12N15/12

CPC分类号： C07K14/705 ,  C07K14/47 ,  C07K2319/02

摘要： A DNA encoding a novel protein SMAP-1, which has a signal sequence, is successfully isolated by screening a cDNA library originating in human fetal hepatocytes with the use of an originally developed TMT method. The expression characteristics and structural characteristics of SMAP-1 suggest that it is a molecule having an important role in vivo .